ArticlePharmaceutics2022

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.

Hsin-Yu Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.